Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
Portfolio Pulse from
Ligand Pharmaceuticals reported strong financial results for Q4 and full year 2024, with a 28% growth in royalty revenue. The company reiterated its 2025 financial guidance, projecting revenues of $180-$200 million and adjusted EPS of $6.00-$6.25.
February 27, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ligand Pharmaceuticals reported a 28% increase in royalty revenue for 2024 and reiterated its 2025 guidance, projecting $180-$200 million in revenues and adjusted EPS of $6.00-$6.25.
The strong financial performance and positive guidance for 2025 are likely to boost investor confidence, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100